期刊文献+

羟基喜树碱术后即刻灌注联合维持灌注预防非浸润性膀胱癌复发的长期疗效分析 被引量:14

Long-term Outcomes of Immediate Instillation Combined with Conventional Instillations of high-dose Hydroxycamptothecin for Prevention of Postoperative Recurrence of Non-invasive Bladder Cancer
下载PDF
导出
摘要 目的:总结大剂量羟基喜树碱即刻灌注联合维持灌注预防非肌层浸润性膀胱癌术后复发的疗效。方法:回顾性分析了167例中、高危非肌层浸润性膀胱尿路上皮癌患者的临床资料.男性116例,女性51例,平均年龄51岁。所有患者均经病理诊断证实,分期为Ta71例、T_196例,分级为G_166例、G_250例、G_351例。患者行经尿道膀胱肿瘤电切术后即刻膀胱内灌注羟基喜树碱40mg,保留20~30 min,术后1w开始羟基喜树碱维持灌注,40 mg/次,1次/w×8次,以后1次/月×10次,每次维持2 h。结果:155例患者获得随访,平均随访期92(72~112)个月。患者1、2和5年肿瘤复发率分别为23.2%、31.6%和41.3%。治疗的长期预后因素包括肿瘤的分级、分期、数目和大小。本组中膀胱Ⅰ、Ⅱ和Ⅲ度不良反应的发生率为13.5%、3.2%和1.9%,未见Ⅳ度不良反应。全身不良反应仅见Ⅰ度不良反应,发生率为1.3%。结论:大剂量羟基喜树碱即刻灌注联合维持灌注预防膀胱癌术后复发的长期疗效较为满意,不良反应发生率低,患者多能良好耐受治疗。 Objective: To analyze the long-term results of high-dose hydroxycamptothecin ( HCPT ) immediate intravesical instil- lation combined with conventional intravesical instillations for preventing postoperative recurrence of non-muscle invasive bladder can- cer. Methods: The clinical data of 167 patients with intermediate and high-risk urothelial tumor of the bladder treated with transurethral resection of bladder tumor ( TUR-Bt ) were reviewed. A total of 116 males and 51 females were identified, with a median age of 51 years, and diagnosed pathologically. Seventy-one patients had pathological stage of T~ and 96 had T~. Sixty-six had grade l, 50 had grade 2, and 51 had grade 3. Intravesical instillation of 40 mg HCPT was immediately administered postoperatively and retained in the bladder for 20 to 30 min. Conventional intravesical instillations were performed 1 wk post-TUR-Bt. HCPT ( 40 mg ) were given once a wk for 8 wk, then monthly for 10 months, and retained for 2 h at each instance. Results: One hundred and fifty-five patients were fol- lowed up. The mean follow-up time was 92 months ( 72 months to 112 months ). The 1-, 2-, and 5-year recurrence rates were 23.2%, 31.6%, and 41.3%, respectively. The long-term prognostic factors of recurrence were grades, stages, numbers, and diameters of tumors. The incidence rates of grades [, II, and l]I local toxic effects were 13.5%, 3.2%, and 1.9%, respectively. No grade IV local toxic ef- fects were observed. Only grade I systemic toxic effects were seen in our series, with an incidence rate of 1.3%. Conclusion: Immedi- ate instillation combined with conventional instillations of high-dose HCPT is effective for long-term prevention of post-operative recur- rence of non-muscle invasive bladder cancer. This procedure could be tolerated by most patients, with few side effects.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2012年第2期105-106,109,共3页 Chinese Journal of Clinical Oncology
关键词 膀胱癌 羟基喜树碱 膀胱灌注 Bladder cancer Hydroxycamptothecin Intravesical instillation
  • 相关文献

参考文献9

二级参考文献37

  • 1朱江,谢桐.125例羟基喜树碱灌注防治膀胱肿瘤的长期随访观察[J].肿瘤,1994,14(5):249-250. 被引量:7
  • 2郝鹏,秦迎春,宋革.膀胱肿瘤术后不同药物膀胱灌注的临床观察[J].黑龙江医药科学,2005,28(6):71-72. 被引量:7
  • 3田溪泉,邢念增,王勇,李建兴.早期吡柔比星膀胱内灌注预防膀胱癌术后复发[J].临床泌尿外科杂志,2006,21(1):4-6. 被引量:35
  • 4彭新庆,阮贤球.浅表性膀胱癌45例治疗分析[J].广西医科大学学报,2007,24(1):137-138. 被引量:3
  • 5LAUFER M, RAMALINGAM S, SCHOENBERG M P, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma, of the bladder: a phase I and pharmacokinetic study[J]. J Clin Oncol, 2003, 21 (4): 697-703.
  • 6ALBINI A, IWAMOTO Y, KLEINMAN H K, et al. A rapid in vitro assay for quantitating the invasion potential of tumor cells[ J ]. Cancer Res, 1987, 47 (12): 3239-3245.
  • 7KANTOR J O, MCCORMICK B, STEEG P S, et al. Inhibition of cell mobility after nm23 transfection of human and murine tumor cells[J]. Cancer Res, 1993, 53(9): 1971-1973.
  • 8KUMAGAI H, TAJIMA M, UENO Y. Effect of cyclic RGD peptide on cell adhesion and tumor metastasis[J]. Biochem Biophys Res Comm, 1991, 177 ( 1 ): 74-82.
  • 9BAJKOWSKI A S, FRANKFATER A. Specific spectrophotometric assays for cathepsin B1[J]. Anal Biochem, 1975, 68 (1): 119-127.
  • 10YANG Z J, SRIRANGANATHAN N, VAUGHT T, et al. A dye-based lymphocyte proliferation assay that permits mutiple immunological analyses: mRNA, cytogenenic, apoptosis, and immunophenotyping studies[J]. J Immunol Methods, 1997,210( 1 ): 25-39.

共引文献51

同被引文献80

引证文献14

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部